These findings were further supported by in vivo experiments, where LDC1267 treatment significantly reduced metastatic spread in murine models of melanoma and mammary cancer, emphasizing the therapeutic potential of modulating AXL activity in cancer immunotherapy. Here, AXL is linked to breast cancer.